HIV Infections, Lymphoma, Non-Hodgkin
Conditions
Keywords
Lymphoma, Large-Cell, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Zidovudine, Bone Marrow Transplantation
Brief summary
To determine whether zidovudine (AZT) in conjunction with bone marrow transplantation prevents the reinfection of donor hematopoietic/lymphoid cells in patients with positive HTLV III antibody and large cell/diffuse histiocytic lymphoma. Patients who are candidates will be evaluated for HTLV III activity and drug levels.
Interventions
DRUGZidovudine
Sponsors
Glaxo Wellcome
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
12 Years to 50 Years
Healthy volunteers
No
Exclusion criteria
Co-existing Condition: Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded. Concurrent Medication: Excluded: * Other anti-retroviral agents. Patients with current life-threatening infection at time of transplant that would preclude a transplant are excluded. Patients must be: * HTLV III antibody positive by ELISA or Western blot or HTLV III viremia. * At high mortal risk with a diagnosis of AIDS or AIDS Related Complex (ARC). * Also patient must fall into one of the following categories: * Have an HIV seronegative identical twin to serve as a bone marrow donor. * Have documentation of large cell/diffuse histiocytic lymphoma/DPDL. * Be a good risk candidate for bone marrow transplant.
Countries
United States
Outcome results
None listed